L. Kuzenkova

[Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience].

A. Kurenkov, L. Kuzenkova, B. Bursagova, 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid].

N. Zavadenko, L. Kuzenkova, N. Suvorinova, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

The efficacy and safety of nusinersen within the expanded access program in Russia

D. Vlodavets, D. Parshin, L. Kuzenkova, 2020, Neuromuscular Diseases.

[Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].

T. T. Batysheva, L. Namazova-Baranova, A. Agranovich, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV-V)].

A. Kurenkov, L. Kuzenkova, B. Bursagova, 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea

I. Fedonyuk, E. E. Tabe, M. N. Sarzhina, 2022, Neurology, Neuropsychiatry, Psychosomatics.

[The First Russian Consensus on the Multilevel Abobotulinumtoxin A Injections in Spastic Forms of Cerebral Palsy].

S. N. Medvedeva, V. Zykov, L. Namazova-Baranova, 2016, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Changes of the spasticity patterns in children with cerebral palsy GMFCS III at the age of 2 to 12 years].

A. Kurenkov, L. Kuzenkova, B. Bursagova, 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Selection of a dose of the botulinum toxin A in spastic forms of cerebral palsy].

L. Namazova-Baranova, A. Kurenkov, L. Kuzenkova, 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.